Literature DB >> 22984649

A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.

Yatan Pal Singh Balhara1, Raka Jain.   

Abstract

OBJECTIVE: The objective of the current study was to explore the difference in treatment adherence to directly supervised buprenorphine and take-home buprenorphine/ naloxone combination for opioid substitution therapy. Urinalysis findings have been used to check treatment adherence on opioid substitution therapy agent. Additionally the study aimed to explore the misuse rate of buprenorphine/naloxone combination based on urinalysis findings.
DESIGN: Cross-sectional chart reviewSetting: Laboratory of a tertiary care drug dependence treatment centerParticipants: One-year laboratory urinalysis records of a tertiary care, drug-dependence treatment center in India were analyzed. All the urine samples of subjects on opioid substitution therapy with buprenorphine or buprenorphine/naloxone combination were included in the study. MEASUREMENTS: Urinalysis using thin layer chromatography for buprenorphine and naloxone. In between group difference for treatment adherence on buprenorphine and buprenorphine/ naloxone combination was done using Mantel-Haenszel test.
RESULTS: A higher proportion of samples from subjects on buprenorphine/naloxone tested positive for buprenorphine as compared to subjects on buprenorphine. Twelve (7.6%) urine samples from patients on buprenorphine/naloxone tested positive for naloxone.
CONCLUSIONS: The findings of the current study suggest that buprenorphine/naloxone combination has a higher adherence rate as compared to buprenorphine when used for opioid substitution therapy.

Entities:  

Keywords:  Buprenorphine; buprenorphine/naloxone; urinalysis

Year:  2012        PMID: 22984649      PMCID: PMC3442748     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  26 in total

1.  Utility of thin layer chromatography for detection of opioids and benzodiazepines in a clinical setting.

Authors:  R Jain
Journal:  Addict Behav       Date:  2000 May-Jun       Impact factor: 3.913

2.  Crushing buprenorphine tablets.

Authors:  Peter Muhleisen; James Spence; Suzi Nielsen
Journal:  Drug Alcohol Rev       Date:  2003-12

3.  A case series of buprenorphine/naloxone treatment in a primary care practice.

Authors:  Benjamin Doolittle; William Becker
Journal:  Subst Abus       Date:  2011-10       Impact factor: 3.716

Review 4.  Office-based buprenorphine treatment for opioid-dependent patients.

Authors:  Elinore F McCance-Katz
Journal:  Harv Rev Psychiatry       Date:  2004 Nov-Dec       Impact factor: 3.732

5.  Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care.

Authors:  P Todd Korthuis; Jessica Gregg; Wendy E Rogers; Dennis McCarty; Christina Nicolaidis; Joshua Boverman
Journal:  J Addict Med       Date:  2010-12       Impact factor: 3.702

6.  Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.

Authors:  E C Strain; G E Bigelow; I A Liebson; M L Stitzer
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

7.  Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Authors:  Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

8.  French field experience with buprenorphine.

Authors:  Marc Auriacombe; Mélina Fatséas; Jacques Dubernet; Jean-Pierre Daulouède; Jean Tignol
Journal:  Am J Addict       Date:  2004

9.  A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence.

Authors:  James Bell; Marian Shanahan; Carolyn Mutch; Felicity Rea; Anni Ryan; Robert Batey; Adrian Dunlop; Adam Winstock
Journal:  Addiction       Date:  2007-09-03       Impact factor: 6.526

10.  A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone).

Authors:  Kaarlo Simojoki; Helena Vorma; Hannu Alho
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-06-17
View more
  2 in total

1.  Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.

Authors:  Kelly Dunn; Anthony DeFulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Psychol Addict Behav       Date:  2014-08-18

Review 2.  A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.

Authors:  Michelle R Lofwall; Sharon L Walsh
Journal:  J Addict Med       Date:  2014 Sep-Oct       Impact factor: 3.702

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.